{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:31:47Z","timestamp":1785760307845,"version":"3.56.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000270","name":"Natural Environment Research Council","doi-asserted-by":"publisher","award":["NE\/H019456\/1"],"award-info":[{"award-number":["NE\/H019456\/1"]}],"id":[{"id":"10.13039\/501100000270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000270","name":"Natural Environment Research Council","doi-asserted-by":"publisher","award":["NE\/H019456\/1"],"award-info":[{"award-number":["NE\/H019456\/1"]}],"id":[{"id":"10.13039\/501100000270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000292","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","award":["VIA 045"],"award-info":[{"award-number":["VIA 045"]}],"id":[{"id":"10.13039\/501100000292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000292","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","award":["VIA 045"],"award-info":[{"award-number":["VIA 045"]}],"id":[{"id":"10.13039\/501100000292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000292","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","award":["VIA 045"],"award-info":[{"award-number":["VIA 045"]}],"id":[{"id":"10.13039\/501100000292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000292","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","award":["VIA 045"],"award-info":[{"award-number":["VIA 045"]}],"id":[{"id":"10.13039\/501100000292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000292","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","award":["VIA 045"],"award-info":[{"award-number":["VIA 045"]}],"id":[{"id":"10.13039\/501100000292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000292","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","award":["VIA 045"],"award-info":[{"award-number":["VIA 045"]}],"id":[{"id":"10.13039\/501100000292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Microbiome"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Acute pulmonary exacerbations (PEx) are associated with increased morbidity and earlier mortality for people living with cystic fibrosis (pwCF). The most common causes of PEx in CF are by bacterial infection and concomitant inflammation leading to progressive airway damage. To draw attention to the seriousness of PEx they have been labelled as \u2018lung attacks\u2019, much like a \u2018heart attack\u2019 for acute myocardial infarction. Treatment typically starts when a pwCF presents with worsening respiratory symptoms. Hence, there is a pressing need to identify indicative biomarkers of PEx onset to allow more timely intervention. Set within an ecological framework, we investigated temporal microbiota dynamics to connect changes in the lung microbiota of pwCF to changes in disease states across a PEx event.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Species-time relationships (STR) describe how the richness of a community changes with time, here STRs were used to assess temporal turnover (<jats:italic>w<\/jats:italic>) within the lung microbiota of each pwCF (<jats:italic>n<\/jats:italic>\u2009=\u200912, mean sample duration 315.9\u2009\u00b1\u200942.7\u00a0days). STRs were characterised by high interpatient variability, indicating that turnover and hence temporal organization are a personalized feature of the CF lung microbiota. Greater turnover was found to be significantly associated with greater change in lung function with time. When microbiota turnover was examined at a finer scale across each pwCF time series, <jats:italic>w<\/jats:italic>-values could clearly be observed to increase in the exacerbation period, then peaking within the treatment period, demonstrating that increases in turnover were not solely a result of perturbations caused by PEx antibiotic interventions. STR <jats:italic>w<\/jats:italic>-values have been found to have a remarkable degree of similarity for different organisms, in a variety of habitats and ecosystems, and time lengths (typically not exceeding <jats:italic>w<\/jats:italic>\u2009=\u20090.5). Here, we found <jats:italic>w<\/jats:italic>-values soon increased beyond that. It was therefore possible to use the departure from that expected norm up to start of treatment to approximate onset of PEx in days (21.2\u2009\u00b1\u20098.9\u00a0days across the study participants).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Here, we illustrate that changes in turnover of the lung microbiota of pwCF can be indicative of PEx onset in considerable advance of when treatment would normally be initiated. This offers translational potential to enable early detection of PEx and consequent timely intervention.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40168-025-02143-5","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T06:40:26Z","timestamp":1749278426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Species turnover within cystic fibrosis lung microbiota is indicative of acute pulmonary exacerbation onset"],"prefix":"10.1186","volume":"13","author":[{"given":"Leah","family":"Cuthbertson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Hatfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Gavillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hardman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian W.","family":"Rivett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"van der Gast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"key":"2143_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1183\/09059180.00006512","volume":"22","author":"JM Bhatt","year":"2013","unstructured":"Bhatt JM. Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev. 2013;22:205. https:\/\/doi.org\/10.1183\/09059180.00006512.","journal-title":"Eur Respir Rev"},{"key":"2143_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.chest.2020.09.084","volume":"159","author":"GE Stanford","year":"2021","unstructured":"Stanford GE, Dave K, Simmonds NJ. Pulmonary exacerbations in adults with cystic fibrosis: a grown-up issue in a changing cystic fibrosis landscape. Chest. 2021;159:93-102. https:\/\/doi.org\/10.1016\/j.chest.2020.09.084.","journal-title":"Chest"},{"key":"2143_CR3","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1136\/thx.2011.161117","volume":"66","author":"K de Boer","year":"2011","unstructured":"de Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, Freitag A, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax. 2011;66:680-5. https:\/\/doi.org\/10.1136\/thx.2011.161117.","journal-title":"Thorax"},{"key":"2143_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/thx.2010.156760","volume":"66","author":"JM FitzGerald","year":"2011","unstructured":"FitzGerald JM. Targeting lung attacks. Thorax. 2011;66:365-6. https:\/\/doi.org\/10.1136\/thx.2010.156760.","journal-title":"Thorax"},{"key":"2143_CR5","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jaip.2017.05.001","volume":"5","author":"JR Castillo","year":"2017","unstructured":"Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017;5:918-27. https:\/\/doi.org\/10.1016\/j.jaip.2017.05.001.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2143_CR6","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0103-2017","volume":"27","author":"C Viniol","year":"2018","unstructured":"Viniol C, Vogelmeier CF. Exacerbations of COPD. Eur Respir Rev. 2018;27:170103. https:\/\/doi.org\/10.1183\/16000617.0103-2017.","journal-title":"Eur Respir Rev"},{"key":"2143_CR7","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1055\/s-0039-1697975","volume":"40","author":"CH Goss","year":"2019","unstructured":"Goss CH. Acute pulmonary exacerbation in cystic fibrosis. Semin Respir Crit Care Med. 2019;40:792\u2013803. https:\/\/doi.org\/10.1055\/s-0039-1697975.","journal-title":"Semin Respir Crit Care Med"},{"key":"2143_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2024-002456","volume":"11","author":"M Almulhem","year":"2024","unstructured":"Almulhem M, Ward C, Haq I, Gray RD, Brodlie M. Definitions of pulmonary exacerbation in people with cystic fibrosis: a scoping review. BMJ Open Respir Res. 2024;11:e002456. https:\/\/doi.org\/10.1136\/bmjresp-2024-002456.","journal-title":"BMJ Open Respir Res"},{"key":"2143_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40168-020-00810-3","volume":"8","author":"L Cuthbertson","year":"2020","unstructured":"Cuthbertson L, Walker AW, Oliver AE, Rogers GB, Rivett DW, Hampton TH, et al. Lung function and microbiota diversity in cystic fibrosis. Microbiome. 2020;8:45. https:\/\/doi.org\/10.1186\/s40168-020-00810-3.","journal-title":"Microbiome"},{"key":"2143_CR10","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1183\/09031936.00080312","volume":"40","author":"PH Quanjer","year":"2012","unstructured":"Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324. https:\/\/doi.org\/10.1183\/09031936.00080312.","journal-title":"Eur Respir J"},{"key":"2143_CR11","doi-asserted-by":"publisher","first-page":"12350","DOI":"10.1038\/s41598-017-10945-3","volume":"7","author":"M van Horck","year":"2017","unstructured":"van Horck M, Winkens B, Wesseling G, van Vliet D, van de Kant K, Vaassen S, et al. Early detection of pulmonary exacerbations in children with Cystic Fibrosis by electronic home monitoring of symptoms and lung function. Sci Rep. 2017;7:12350. https:\/\/doi.org\/10.1038\/s41598-017-10945-3.","journal-title":"Sci Rep"},{"key":"2143_CR12","doi-asserted-by":"publisher","first-page":"e00419","DOI":"10.1128\/spectrum.00419-22","volume":"10","author":"H Gavillet","year":"2022","unstructured":"Gavillet H, Hatfield L, Rivett D, Jones A, Maitra A, Horsley A, et al. Bacterial culture underestimates lung pathogen detection and infection status in cystic fibrosis. Microbiol Spectr. 2022;10:e00419-22. https:\/\/doi.org\/10.1128\/spectrum.00419-22.","journal-title":"Microbiol Spectr"},{"key":"2143_CR13","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.jcf.2014.03.010","volume":"13","author":"AR Smyth","year":"2014","unstructured":"Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P, et al. European Cystic Fibrosis Society standards of care: best practice guidelines. J Cyst Fibros. 2014;13:S23-S42. https:\/\/doi.org\/10.1016\/j.jcf.2014.03.010.","journal-title":"J Cyst Fibros"},{"key":"2143_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","volume":"2","author":"TWR Lee","year":"2003","unstructured":"Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2:29-34. https:\/\/doi.org\/10.1016\/S1569-1993(02)00141-8.","journal-title":"J Cyst Fibros"},{"key":"2143_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.07.009","author":"DA Hughes","year":"2022","unstructured":"Hughes DA, Rosenthal M, Cuthbertson L, Ramadan N, Felton I, Simmonds NJ, et al. An invisible threat? Aspergillus positive cultures and co-infecting bacteria in airway samples. J Cyst Fibros. 2022. https:\/\/doi.org\/10.1016\/j.jcf.2022.07.009.","journal-title":"J Cyst Fibros"},{"key":"2143_CR16","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jcf.2022.04.017","volume":"21","author":"CF Zirbes","year":"2022","unstructured":"Zirbes CF, Pitcher NJ, Davis JC, Bartels AR, Krogh JD, Teresi M, et al. Staphylococcus aureus detection from CF respiratory samples is improved using alternative media. J Cyst Fibros. 2022;21:888-9. https:\/\/doi.org\/10.1016\/j.jcf.2022.04.017.","journal-title":"J Cyst Fibros"},{"key":"2143_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40168-024-01780-6","volume":"12","author":"H Gavillet","year":"2024","unstructured":"Gavillet H, Hatfield L, Jones A, Maitra A, Horsley A, Rivett D, et al. Ecological patterns and processes of temporal turnover within lung infection microbiota. Microbiome. 2024;12:63. https:\/\/doi.org\/10.1186\/s40168-024-01780-6.","journal-title":"Microbiome"},{"key":"2143_CR18","doi-asserted-by":"publisher","unstructured":"Rivett DW, Hatfield LR, Gavillet H, Hardman M, van der Gast C. Bacterial interactions underpin worsening lung function in cystic fibrosis-associated infections. mBio. 2024;0:e01456-24. https:\/\/doi.org\/10.1128\/mbio.01456-24.","DOI":"10.1128\/mbio.01456-24"},{"key":"2143_CR19","doi-asserted-by":"publisher","unstructured":"Raghuvanshi R, Vasco K, V\u00e1zquez-Baeza Y, Jiang L, Morton James T, Li D, et al. High-resolution longitudinal dynamics of the cystic fibrosis sputum microbiome and metabolome through antibiotic therapy. mSystems. 2020;5:e00292-20. https:\/\/doi.org\/10.1128\/mSystems.00292-20.","DOI":"10.1128\/mSystems.00292-20"},{"key":"2143_CR20","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1038\/s41467-024-49150-y","volume":"15","author":"S Widder","year":"2024","unstructured":"Widder S, Carmody LA, Opron K, Kalikin LM, Caverly LJ, LiPuma JJ. Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis. Nat Commun. 2024;15:4889. https:\/\/doi.org\/10.1038\/s41467-024-49150-y.","journal-title":"Nat Commun"},{"key":"2143_CR21","doi-asserted-by":"publisher","unstructured":"Hampton TH, Thomas D, van der Gast C, O\u2019Toole GA, Stanton BA. Mild cystic fibrosis lung disease is associated with bacterial community stability. Microbiol Spectr. 2021;9:10.1128\/spectrum.00029-21. https:\/\/doi.org\/10.1128\/spectrum.00029-21.","DOI":"10.1128\/spectrum.00029-21"},{"key":"2143_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/ele.14481","volume":"27","author":"H Yin","year":"2024","unstructured":"Yin H, Rudolf VHW. Time is of the essence: a general framework for uncovering temporal structures of communities. Ecol Lett. 2024;27:e14481. https:\/\/doi.org\/10.1111\/ele.14481.","journal-title":"Ecol Lett"},{"key":"2143_CR23","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1038\/s41396-021-00976-0","volume":"15","author":"DW Rivett","year":"2021","unstructured":"Rivett DW, Mombrikotb SB, Gweon HS, Bell T, van der Gast C. Bacterial communities in larger islands have reduced temporal turnover. ISME J. 2021;15:2947-55. https:\/\/doi.org\/10.1038\/s41396-021-00976-0.","journal-title":"ISME J"},{"key":"2143_CR24","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1186\/s13059-014-0531-y","volume":"15","author":"GE Flores","year":"2014","unstructured":"Flores GE, Caporaso JG, Henley JB, Rideout JR, Domogala D, Chase J, et al. Temporal variability is a personalized feature of the human microbiome. Genome Biol. 2014;15:531. https:\/\/doi.org\/10.1186\/s13059-014-0531-y.","journal-title":"Genome Biol"},{"key":"2143_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S2213-2600(14)70028-1","volume":"2","author":"RP Dickson","year":"2014","unstructured":"Dickson RP, Erb-Downward JR, Huffnagle GB. Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Respir Med. 2014;2:238-46. https:\/\/doi.org\/10.1016\/S2213-2600(14)70028-1.","journal-title":"Lancet Respir Med"},{"key":"2143_CR26","doi-asserted-by":"publisher","unstructured":"Whiteson KL, Bailey B, Bergkessel M, Conrad D, Delhaes L, Felts B, et al. The upper respiratory tract as a microbial source for pulmonary infections in cystic fibrosis. parallels from island biogeography. Am J Respir Crit Care Med. 2014;189:1309-15. https:\/\/doi.org\/10.1164\/rccm.201312-2129PP.","DOI":"10.1164\/rccm.201312-2129PP"},{"key":"2143_CR27","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/ismej.2015.198","volume":"10","author":"L Cuthbertson","year":"2016","unstructured":"Cuthbertson L, Rogers GB, Walker AW, Oliver A, Green LE, Daniels TWV, et al. Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention. ISME J. 2016;10:1081-91. https:\/\/doi.org\/10.1038\/ismej.2015.198.","journal-title":"ISME J"},{"key":"2143_CR28","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1073\/pnas.1120577109","volume":"109","author":"J Zhao","year":"2012","unstructured":"Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci USA. 2012;109:5809-14. https:\/\/doi.org\/10.1073\/pnas.1120577109.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2143_CR29","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jcf.2014.10.004","volume":"14","author":"L Cuthbertson","year":"2015","unstructured":"Cuthbertson L, Rogers GB, Walker AW, Oliver A, Hoffman LR, Carroll MP, et al. Implications of multiple freeze-thawing on respiratory samples for culture-independent analyses. J Cyst Fibrosis. 2015;14:464-7. https:\/\/doi.org\/10.1016\/j.jcf.2014.10.004.","journal-title":"J Cyst Fibrosis"},{"key":"2143_CR30","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1128\/jcm.00764-14","volume":"52","author":"L Cuthbertson","year":"2020","unstructured":"Cuthbertson L, Rogers Geraint B, Walker Alan W, Oliver A, Hafiz T, Hoffman Lucas R, et al. Time between collection and storage significantly influences bacterial sequence composition in sputum samples from cystic fibrosis respiratory infections. J Clin Microbiol. 2020;52:3011-6. https:\/\/doi.org\/10.1128\/jcm.00764-14.","journal-title":"J Clin Microbiol"},{"key":"2143_CR31","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1128\/jcm.02282-05","volume":"44","author":"GB Rogers","year":"2006","unstructured":"Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Kehagia V, et al. Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. J Clin Microbiol. 2006;44:2601-4. https:\/\/doi.org\/10.1128\/jcm.02282-05.","journal-title":"J Clin Microbiol"},{"key":"2143_CR32","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/ismej.2012.145","volume":"7","author":"GB Rogers","year":"2013","unstructured":"Rogers GB, Cuthbertson L, Hoffman LR, Wing PAC, Pope C, Hooftman DAP, et al. Reducing bias in bacterial community analysis of lower respiratory infections. ISME J. 2013;7:697-706. https:\/\/doi.org\/10.1038\/ismej.2012.145.","journal-title":"ISME J"},{"key":"2143_CR33","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/1758-2229.12159","volume":"6","author":"AE Oliver","year":"2014","unstructured":"Oliver AE, Newbold LK, Whiteley AS, van der Gast CJ. Marine bacterial communities are resistant to elevated carbon dioxide levels. Environ Microbiol Rep. 2014;6:574-82. https:\/\/doi.org\/10.1111\/1758-2229.12159.","journal-title":"Environ Microbiol Rep"},{"key":"2143_CR34","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1111\/j.1462-2920.2007.01550.x","volume":"10","author":"CJ van der Gast","year":"2008","unstructured":"van der Gast CJ, Ager D, Lilley AK. Temporal scaling of bacterial taxa is influenced by both stochastic and deterministic ecological factors. Environ Microbiol. 2008;10:1411-8. https:\/\/doi.org\/10.1111\/j.1462-2920.2007.01550.x.","journal-title":"Environ Microbiol"},{"key":"2143_CR35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1128\/jcm.01324-09","volume":"48","author":"GB Rogers","year":"2010","unstructured":"Rogers GB, Skelton S, Serisier DJ, van der Gast CJ, Bruce KD. Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling. J Clin Microbiol. 2010;48:78-86. https:\/\/doi.org\/10.1128\/jcm.01324-09.","journal-title":"J Clin Microbiol"},{"key":"2143_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jcf.2019.05.020","volume":"19","author":"A Singh","year":"2020","unstructured":"Singh A, He M, Chen V, Hollander Z, Tebbutt SJ, Ng RT, et al. Blood biomarkers to predict short-term pulmonary exacerbation risk in children and adolescents with CF: a pilot study. J Cyst Fibros. 2020;19:49-51. https:\/\/doi.org\/10.1016\/j.jcf.2019.05.020.","journal-title":"J Cyst Fibros"},{"key":"2143_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12931-023-02630-z","volume":"24","author":"C Martin","year":"2023","unstructured":"Martin C, Guzior DV, Gonzalez CT, Okros M, Mielke J, Padillo L, et al. Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor\u2013Tezacaftor\u2013Ivacaftor therapy. Respir Res. 2023;24:317. https:\/\/doi.org\/10.1186\/s12931-023-02630-z.","journal-title":"Respir Res"},{"key":"2143_CR38","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/j.1462-2920.2009.02107.x","volume":"12","author":"D Ager","year":"2010","unstructured":"Ager D, Evans S, Li H, Lilley AK, van der Gast CJ. Anthropogenic disturbance affects the structure of bacterial communities. Environ Microbiol. 2010;12:670-8. https:\/\/doi.org\/10.1111\/j.1462-2920.2009.02107.x.","journal-title":"Environ Microbiol"},{"key":"2143_CR39","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1513\/AnnalsATS.202111-1266OC","volume":"19","author":"SC Carter","year":"2022","unstructured":"Carter SC, Franciosi AN, O\u2019Shea KM, O\u2019Carroll OM, Sharma A, Bell A, et al. Acute pulmonary exacerbation phenotypes in patients with cystic fibrosis. Ann Am Thorac Soc. 2022;19:1818-26. https:\/\/doi.org\/10.1513\/AnnalsATS.202111-1266OC.","journal-title":"Ann Am Thorac Soc"},{"key":"2143_CR40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1378\/chest.09-1103","volume":"137","author":"R Amin","year":"2010","unstructured":"Amin R, Dupuis A, Aaron SD, Ratjen F. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest. 2010;137:171-6. https:\/\/doi.org\/10.1378\/chest.09-1103.","journal-title":"Chest"},{"key":"2143_CR41","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1513\/AnnalsATS.202306-576OC","volume":"21","author":"CS Thornton","year":"2024","unstructured":"Thornton CS, Caverly LJ, Kalikin LM, Carmody LA, McClellan S, LeBar W, et al. Prevalence and clinical impact of respiratory viral infections from the STOP2 study of cystic fibrosis pulmonary exacerbations. Ann Am Thorac Soc. 2024;21:595-603. https:\/\/doi.org\/10.1513\/AnnalsATS.202306-576OC.","journal-title":"Ann Am Thorac Soc"},{"key":"2143_CR42","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1378\/chest.12-1005","volume":"143","author":"PC Goeminne","year":"2013","unstructured":"Goeminne PC, Kici\u0144ski M, Vermeulen F, Fierens F, De Boeck K, Nemery B, et al. Impact of air pollution on cystic fibrosis pulmonary exacerbations: a case-crossover analysis. Chest. 2013;143:946-54. https:\/\/doi.org\/10.1378\/chest.12-1005.","journal-title":"Chest"},{"key":"2143_CR43","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/ismej.2013.54","volume":"7","author":"A Shade","year":"2013","unstructured":"Shade A, Gregory Caporaso J, Handelsman J, Knight R, Fierer N. A meta-analysis of changes in bacterial and archaeal communities with time. ISME J. 2013;7:1493-506. https:\/\/doi.org\/10.1038\/ismej.2013.54.","journal-title":"ISME J"},{"key":"2143_CR44","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.0030-1299.2006.14223.x","volume":"112","author":"EP White","year":"2006","unstructured":"White EP, Adler PB, Lauenroth WK, Gill RA, Greenberg D, Kaufman DM, et al. A comparison of the species-time relationship across ecosystems and taxonomic groups. Oikos. 2006;112:185-95.","journal-title":"Oikos"},{"key":"2143_CR45","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jcf.2024.04.004","volume":"23","author":"JD Cogen","year":"2024","unstructured":"Cogen JD, Quon BS. Update on the diagnosis and management of cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2024;23:603-11. https:\/\/doi.org\/10.1016\/j.jcf.2024.04.004.","journal-title":"J Cyst Fibros"},{"key":"2143_CR46","doi-asserted-by":"publisher","unstructured":"Sutharsan S, Dillenhoefer S, Welsner M, Stehling F, Brinkmann F, Burkhart M, et al. Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry. Lancet Reg Health Eur. 2023;32. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100690.","DOI":"10.1016\/j.lanepe.2023.100690"},{"key":"2143_CR47","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/ppul.25859","volume":"57","author":"E Kramer-Golinkoff","year":"2022","unstructured":"Kramer-Golinkoff E, Camacho A, Kramer L, Taylor-Cousar JL. A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators. Pediatr Pulmonol. 2022;57:1253-61. https:\/\/doi.org\/10.1002\/ppul.25859.","journal-title":"Pediatr Pulmonol"},{"key":"2143_CR48","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nrmicro1643","volume":"5","author":"JI Prosser","year":"2007","unstructured":"Kramer-Golinkoff E, Camacho A, Kramer L, Taylor-Cousar JL. A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators. Pediatr Pulmonol. 2022;57:1253-61. https:\/\/doi.org\/10.1038\/nrmicro1643.","journal-title":"Nat Rev Microbiol"}],"container-title":["Microbiome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40168-025-02143-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40168-025-02143-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40168-025-02143-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T20:09:35Z","timestamp":1749499775000},"score":1,"resource":{"primary":{"URL":"https:\/\/microbiomejournal.biomedcentral.com\/articles\/10.1186\/s40168-025-02143-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2143"],"URL":"https:\/\/doi.org\/10.1186\/s40168-025-02143-5","relation":{},"ISSN":["2049-2618"],"issn-type":[{"value":"2049-2618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the Southampton and Southwest Hampshire Research Ethics Committee, UK (06\/Q1704\/24). All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}